STRIDES PHARMA SCIENCE LIMITED — Capital/Financing Update 2019

Jul 10, 2019

July 10, 2019

BSE Limited

Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip code: 532531

The National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex Bandra (E) Mumbai - 400 051 Scrip code: STAR

Dear Sirs,

Sub: Strides announces final closure of Arrow transaction

Further to our earlier communication relating to “ Strides to exit its investment in Arrow for AUD 394 Million” , we wish to inform you that the transaction has achieved final closure. Strides Pharma Global Pte Limited, a step-down subsidiary of the Company in Singapore has received AUD 300 Million immediately at closing, while the balance AUD 94 Million will be a deferred consideration backed by a secured interest-bearing instrument. All proceeds net of transaction cost will be used to pare down debt.

Strides shall retain global access to IP’s of over 140 products and has concurrently entered into a preferred supply agreement with Arrow and Apotex as the major supplier which will enable Strides to retain profits equivalent to 40%-50% of current Arrow EBITDA.

You are requested to take the same on record.

For Strides Pharma Science Limited,

==> picture [114 x 47] intentionally omitted <==

Manjula Ramamurthy Company Secretary

==> picture [85 x 83] intentionally omitted <==

Strides Pharma Science Limited

(Formerly Strides Shasun Limited) CIN: L24230MH1990PLC057062 Corp Off : Strides House, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India Tel: +91 80 6784 0000 Fax: +91 80 6784 0700 Regd Off : 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942 info@strides.com; www.strides.com